Comparative Analysis of Manual ELISA and Ella, an Automated Instrument for ELISA, in Measuring Serum Galectin-3 Levels in Breast Cancer Patient Samples
Open Access
Abstract
Background: Circulating galectin-3 (Gal-3) levels have been indicated as a promising diagnostic, prognostic, and therapeutic target in breast cancer patients. Specifically, serum galectin-3 levels are traditionally measured using manual Enzyme-Linked Immunosorbent Assay (ELISA), but recent automated methods, such as Simple Plex assay by ProteinSimple™ run on an Ella instrument, have shown promising evidence of being more efficient and less error-prone than manual methods. This paper aims to assess whether there are differences in serum galectin-3 measurements between manual and automated ELISA methods. Methods: Serum galectin-3 levels were initially analyzed from one hundred and fifteen breast cancer samples using both manual ELISA and the Ella instrument. Following coefficient of variation (CV) and outlier analysis, ninety-five samples were analyzed further with JMP statistical software to perform Shapiro-Wilk, Spearman’s correlation, Wilcoxon signed-rank, and regression analyses. Results: The Ella instrument resulted in significantly lower CV values, confirming that it is more precise and reliable than manual ELISA methods. There was a moderate correlation between ELISA and Ella measurements (r = 0.49, p < 0.0001), but a Wilcoxon signed-rank test revealed that serum gaelectin-3 measurements obtained with the Ella instrument were significantly lower compared to those obtained with manual ELISA, with a mean difference of −5.19 ng/mL (p < 0.0001). Regression analysis showed a significant increase in the difference between manual ELISA and Ella measurements as serum galectin-3 levels increase (p < 0.0001). This difference in measurements between manual and automated ELISA techniques remained consistent when analyses were performed within each breast cancer stage, immunophenotype, and histology. Conclusions: While the Ella instrument is a fast and reliable tool, the discrepancies between manual ELISA and the Ella instrument in quantifying serum galectin-3 levels are important to consider prior to widespread use.Keywords
All Related Versions
Funding Information
- Prisma Health
- SOARinG Research Program at the University of South Carolina School of Medicine Greenville
- Department of Biomedical Sciences at the University of South Carolina School of Medicine Greenville
This publication has 54 references indexed in Scilit:
- Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshotReviews in Endocrine and Metabolic Disorders, 2022
- IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanomaCancer Immunology, Immunotherapy, 2017
- Tissue- and cell-specific localization of galectins, β-galactose-binding animal lectins, and their potential functions in health and diseaseAnatomical Science International, 2016
- Key regulators of galectin–glycan interactionsProteomics, 2016
- Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failureClinical Biochemistry, 2014
- Biomarkers in drug safety evaluation2014
- Multi-center determination of galectin-3 assay performance characteristics:Clinical Biochemistry, 2010
- Dynamics of galectin-3 in the nucleus and cytoplasmBiochimica et Biophysica Acta (BBA) - General Subjects, 2010
- Galectin-3: An open-ended storyBiochimica et Biophysica Acta (BBA) - General Subjects, 2006
- Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasisCancer and Metastasis Reviews, 1987